8-K: Applied Therapeutics Announces Leadership Changes, Appoints New Executive Chairman and Interim CEO

Applied Therapeutics has appointed John H. Johnson as Executive Chairman and Les Funtleyder as interim CEO, while Shoshana Shendelman steps down from her roles.

Summary

• Applied Therapeutics has appointed John H. Johnson as Executive Chairman and Chair of the Board, effective December 19, 2024.
• Mr. Johnson will receive an annual base salary of $1,010,250, along with stock options and restricted stock units.
• Les Funtleyder, the company's CFO, has been appointed as interim CEO, also effective December 19, 2024.
• Mr. Funtleyder's annual base salary will increase by $15,000 per month during his tenure as interim CEO, and he will receive a 50% target annual bonus for 2025.
• He will also receive quarterly equity grants and a $525,000 lump sum payment upon FDA approval of the SORD treatment or a change in control.
• Shoshana Shendelman has stepped down from her roles as President, CEO, and Secretary, and as a member of the Board, effective December 19, 2024.
• Ms. Shendelman will receive severance payments and benefits as per her offer letter, plus an additional $2,100,000 lump sum payment for her outstanding stock units.
• The company has withdrawn its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for govorestat for the treatment of Classic Galactosemia.
• The company now expects to submit an NDA for govorestat for the treatment of SORD after the first quarter of 2025.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The appointment of a new Executive Chairman and interim CEO are positive, but the withdrawal of the MAA and the delay in the NDA submission are negative. The departure of the CEO also adds uncertainty.

Positives

• The appointment of John H. Johnson, a recognized leader with extensive experience in the pharmaceutical and biotechnology industry, is a positive move for the company.
• Les Funtleyder's appointment as interim CEO provides continuity and stability during the leadership transition.
• The company is continuing to work with the FDA on the data needed to support an appropriate regulatory pathway for the SORD treatment.

Negatives

• The withdrawal of the MAA to the EMA for govorestat for the treatment of Classic Galactosemia is a setback.
• The delay in submitting the NDA for govorestat for the treatment of SORD until after the first quarter of 2025 is a negative development.
• The departure of the CEO and President, Shoshana Shendelman, creates uncertainty.

Risks

• The company faces risks related to the development, marketing, and commercialization of its product candidates.
• There are risks associated with the timing and results of preclinical studies and clinical trials.
• The company's ability to obtain regulatory approval for its product candidates is uncertain.
• The company's financial position and need for additional financing pose risks.
• The company faces competition in the markets it serves.

Future Outlook

The company expects to submit an NDA for govorestat for the treatment of SORD after the first quarter of 2025. The company is also evaluating its response to the CRL for the Galactosemia treatment and will continue to work with the FDA on the SORD program.

Management Comments

• The company continues to evaluate its response to the CRL for the Galactosemia treatment.
• The company will be closely examining the ongoing Sorbitol Dehydrogenase (SORD) Deficiency clinical development program.
• The company will continue to work with the FDA on the data needed to support an appropriate regulatory pathway for the SORD drug.

Industry Context

The leadership changes at Applied Therapeutics occur within the context of the biotechnology industry, where companies often experience transitions in management as they navigate the complex process of drug development and regulatory approvals. The company's focus on rare diseases and its recent regulatory setbacks are common challenges in this sector.

Comparison to Industry Standards

• The appointment of an Executive Chairman with extensive industry experience is a common practice in the biotechnology sector, similar to companies like Biogen and Amgen who have also appointed experienced leaders to guide their strategic direction.
• The use of interim CEOs during leadership transitions is also a standard practice, as seen in companies like Gilead Sciences and Vertex Pharmaceuticals, which have used interim leaders to maintain stability.
• The severance package provided to Shoshana Shendelman is consistent with industry norms for departing executives, often including a combination of cash payments, continued benefits, and accelerated vesting of equity, similar to packages seen at companies like Regeneron and Incyte.
• The withdrawal of the MAA for Galactosemia is a setback, but not uncommon in the industry, as regulatory hurdles are a significant challenge for drug developers. Companies like Sarepta Therapeutics and BioMarin have also faced similar regulatory challenges.
• The delay in the NDA submission for SORD is also not unusual, as companies often need to gather additional data to support their applications. This is similar to delays experienced by companies like Alnylam Pharmaceuticals and Ultragenyx Pharmaceutical.

Management Changes

Stakeholder Impact

• Shareholders may react negatively to the leadership changes and regulatory setbacks.
• Employees may experience uncertainty due to the changes in leadership.
• Customers and partners may be concerned about the impact of the changes on the company's product development and commercialization plans.
• Creditors may be concerned about the company's financial stability.

Next Steps

• The company will continue to evaluate its response to the CRL for the Galactosemia treatment.
• The company will closely examine the ongoing Sorbitol Dehydrogenase (SORD) Deficiency clinical development program.
• The company will continue to work with the FDA on the data needed to support an appropriate regulatory pathway for the SORD drug.
• The company expects to submit an NDA for govorestat for the treatment of SORD after the first quarter of 2025.

Key Dates

Keywords

Executive Chairman, Interim CEO, Leadership Change, Sorbitol Dehydrogenase, Galactosemia, FDA, NDA, MAA, Regulatory Approval, Biotechnology